Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Palbociclib in Hormone-Receptor–Positive Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Jungsil Ro et al.|New England Journal of Medicine|2015Cited by 1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAlessandra Gennari, Nadia Harbeck, Hope S. Rugo et al.|Annals of Oncology|2021Cited by 1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNicholas C. Turner, Massimo Cristofanilli, Dennis J. Slamon et al.|New England Journal of Medicine|2018Cited by 1.3k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Stefan Michiels et al.|Annals of Oncology|2014Cited by 1.3k